Icahn gets Legault onto Forest's board
This article was originally published in Scrip
Activist investor Carl Icahn has succeeded in securing board representation at Forest Laboratories. One of his four candidates, Pierre Legault, former CFO at OSI Pharmaceuticals, beat longstanding board member and chair of Forest's compensation committee Dan Goldwasser to secure one of 10 director positions, giving Mr Icahn increased leverage in his bid to push through change at the company.
You may also be interested in...
The best-seller rankings today are testament to the great success of antibody drug technology developed at the end of the last century, and contrast with the dominance of primary care small molecule drugs that powered big pharma in previous decades. But where did these drugs come from – and where are they going?
Novartis is to acquire the Phase III siRNA drug inclisiran in a cash deal that swells its cardiovascular portfolio. The move will not be welcomed by Amgen, Sanofi or Regeneron.
Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.